Gilead and Kite to Showcase Oncology Portfolio at ASCO 2024

Gilead Sciences, Inc. and its subsidiary Kite will present 18 abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These presentations will highlight significant advancements in treating various types of cancers, including lung, breast, gastrointestinal, colorectal, leukemia, and lymphoma. This underscores Gilead and Kite's dedication to transforming cancer treatment approaches with innovative therapies.

New Insights on Trodelvy in Non-Small Cell Lung Cancer

Gilead will unveil primary results from the Phase 3 EVOKE-01 study comparing Trodelvy® (sacituzumab govitecan-hziy) and docetaxel for patients with advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed following platinum-based chemotherapy and checkpoint inhibitor therapy. Additionally, longer-term data from Cohort A of the Phase 2 EVOKE-02 study will be shared. This study examines Trodelvy in combination with KEYTRUDA® (pembrolizumab) for first-line advanced or metastatic squamous/non-squamous PD-L1-high NSCLC patients.

Advancements in Gastrointestinal Cancer Treatments

A rapid oral presentation will feature an updated analysis from the Phase 2 EDGE-Gastric study, conducted in partnership with Arcus Biosciences. This presentation will include longer-term efficacy and safety results for the Fc-silent anti-TIGIT antibody domvanalimab combined with the anti-PD-1 antibody zimberelimab and chemotherapy as a first-line treatment option for upper gastrointestinal cancers.

Further, an oral presentation with Arcus Biosciences will present data from Cohort B of the ARC-9 study. This Phase 1b/2 study evaluates the safety and efficacy of the dual A2a/b adenosine receptor antagonist etrumadenant, combined with zimberelimab and FOLFOX/bevacizumab, in patients with third-line metastatic colorectal cancer (mCRC).

CAR T-Cell Therapies and Lymphoma Treatments

Kite will present a pilot study evaluating Yescarta® (axicabtagene ciloleucel) for treating patients with relapsed or refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL). This study will shed light on the efficacy and safety of Yescarta for these patient groups with significant unmet clinical needs.

Additionally, updated overall survival outcomes from the pivotal Phase 1/2 ZUMA-3 trial for Tecartus® (brexucabtagene autoleucel) will be shared. This trial, which investigates CAR T-cell therapy for relapsed or refractory B-cell lymphoblastic leukemia (B-ALL), now has over four years of follow-up data, showcasing the long-term survival benefits and durability of Tecartus.

Presentation Overview

The 2024 ASCO Annual Meeting will feature several abstracts covering various tumor types. Highlights include:

- B-cell Acute Lymphoblastic Leukemia: Long-term survival outcomes with brexucabtagene autoleucel (Abstract #6531).
- Biliary Tract Cancer: Phase 2 study of gemcitabine, cisplatin, quemliclustat, and zimberelimab as first-line treatment (Abstract #TPS4195).
- Breast Cancer: Multiple studies, including primary results from randomized trials and genomic analysis (Abstracts #LBA1004, #1101, #1075, #1102, #TPS1140).
- Central Nervous System Lymphoma: Pilot study of axicabtagene ciloleucel for treatment of relapsed/refractory PCNSL and SCNSL (Abstract #2006).
- Colorectal Cancer: Evaluating etrumadenant-based combinations in previously treated metastatic colorectal cancer (Abstract #3508).
- Gastroesophageal Cancers: Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in advanced gastroesophageal cancer (Abstract #433248).
- Lung Cancer: Primary results of sacituzumab govitecan vs. docetaxel in metastatic NSCLC (Abstract #LBA8500) and combination studies with pembrolizumab (Abstract #8592).
- Rare Genitourinary Tumors: Phase II study of sacituzumab govitecan with or without atezolizumab (Abstract #TPS4627).
- Solid Tumors: Pooled safety analysis of sacituzumab govitecan across various solid tumor types (Abstract #3029).
- Thyroid Cancer: Phase 2 trial of sacituzumab govitecan in advanced or metastatic thyroid carcinoma (Abstract #TPS6130).
- Urothelial Cancer: Treatment patterns and combination therapies in metastatic urothelial carcinoma (Abstracts #e16500, #TPS4618).

These presentations exemplify Gilead and Kite’s ongoing efforts to advance cancer treatment and improve patient outcomes through innovative research and development.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!